















http://dx.doUsefulness of Serial B-type Natriuretic Peptide Assessment
in Asymptomatic Aortic StenosisChristine Henri, MDa,b, Julien Magne, PhDa, Raluca Dulgheru, MDa, Laurent Davin, MDa,
Saloua Laaraibi, MDa, Damien Voilliot, MDa, Seisyou Kou, MDa, Alain Nchimi, MDa, Cécile Oury, PhDc,
Luc A. Pierard, MD, PhDa, and Patrizio Lancellotti, MD, PhDa,*















i.org/1agement of asymptomatic patients with aortic stenosis (AS). The aim of this study was to
identify the echocardiographic determinants of BNP changes during follow-up in AS. We
studied 61 asymptomatic patients with greater than moderate AS and preserved left ven-
tricular (LV) ejection fraction who underwent rest and exercise Doppler echocardiography
with concomitant BNP level measurement at baseline. BNP measurement was repeated after
inclusion every 6 months. Patients were divided into 2 groups according to the median of
BNP changes during follow-up. According to parameters at rest, patients in the high BNP
changes group had signiﬁcantly higher E/e0 ratio. Statistically signiﬁcant correlations were
found between BNP changes and E/e0 ratio and indexed left atrial area. According to ex-
ercise parameters, patients in the high BNP changes group had signiﬁcantly lower exercise-
induced increase in LV ejection fraction. Statistically signiﬁcant correlations were found
between BNP changes and exercise-induced changes in LV ejection fraction. After adjust-
ment for age, mean aortic pressure gradient, and BNP level at baseline, multivariate analysis
identiﬁed indexed left atrial area, E/e0 at rest, and exercise-induced increase in ejection
fraction as independent determinants of BNP changes during follow-up. In conclusion, this
study shows that, in asymptomatic patients with preserved LV function and moderate AS,
serial BNP measurements may widely vary. Subclinical LV diastolic and systolic dysfunc-
tions are frequently present in patients with higher serial BNP changes.  2014 Elsevier
Inc. All rights reserved. (Am J Cardiol 2014;114:441e448)Aortic stenosis (AS) is the most common valvular heart
disease.1 Risk stratiﬁcation of asymptomatic patients with
AS and preserved left ventricular ejection fraction (LVEF)
remains challenging. In clinical practice, the risk-beneﬁt
ratio of early surgery should be carefully evaluated, and
aortic valve replacement might be discussed in asymptom-
atic patients considered at high risk.2,3 Exercise echocardi-
ography has been shown to provide incremental prognostic
information beyond echocardiography at rest or exercise
testing alone, even in patients with moderate AS.4 B-type
natriuretic peptide (BNP) is probably the biomarker most
frequently measured in AS; it is predominantly secreted by
ventricular cardiac myocytes in response to increased wall
stress.5 Recent European Society of Cardiology guidelines
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0.1016/j.amjcard.2014.04.053individual risk stratiﬁcation in asymptomatic AS.6 Of note,
interest has recently grown in terms of serial BNP mea-
surements for better prediction of outcome in patients with
valvular heart disease, with a more accurate predictive po-
wer than elective measurements.7,8 However, in AS, little is
known about longitudinal changes in BNP levels during
serial assessments. The aims of the present study were (1) to
prospectively describe the individual changes in BNP levels
during longitudinal follow-up of asymptomatic patients with
AS and preserved LVEF and (2) to identify whether these
changes were related to the presence of baseline left ven-
tricular (LV) systolic and/or diastolic dysfunction.Methods
We prospectively screened 162 consecutive asymptom-
atic patients with at least moderate AS (aortic valve area
<1.5 cm2) and preserved LVEF (i.e., >50%) who were
referred to our Heart Valve Clinic to perform both resting
and exercise Doppler echocardiography with concomitant
BNP level measurement (Figure 1). Sixty-one patients met
the inclusion criteria and had a BNP measurement repeated
after at least 6 months of follow-up and then after each 6 or
12 months, according to the individual management. A
careful history evaluation and exercise testing conﬁrmed
asymptomatic status. The following clinical characteristics
were collected: age, body surface area, gender, dyslipidemia
(cholesterol-lowering medications or low-density lipopro-
tein cholesterol >115 mg/dl), systemic arterial hypertensionwww.ajconline.org
Figure 1. Flowchart of the inclusion and exclusion criteria.
442 The American Journal of Cardiology (www.ajconline.org)(antihypertensive medications or blood pressure >140/
90 mm Hg), diabetes mellitus (oral hypoglycemic medica-
tions, insulin, or glycemia >126 mg/dl), current smoking,
coronary artery disease (history of myocardial infarction or
documented coronary artery stenosis), atrial ﬁbrillation, and
chronic renal insufﬁciency. The relevant institutional review
boards approved the protocol, and all patients gave written
informed consent.
Before the exercise test, comprehensive transthoracic
Doppler echocardiographic examination at rest was per-
formed with a General Electric Vingmed Vivid 9 ultrasound
system (Horten, Norway). The acquisitions were stored on a
dedicated workstation for subsequent off-line analysis
(EchoPAC; General Electric Healthcare, Little Chalfont,BNP changes ðpg=mlÞ ¼ Last BNP at follow-up Baseline BNP at inclusionUnited Kingdom). LV stroke volume was calculated by
multiplying the LV outﬂow tract area by the LV outﬂow
tract velocity-time integral measured by pulse-waveAnnualized BNP changes ðpg=ml=yearÞ ¼ ðLast BNP at follow-up Baseline BNP at inclusionÞ
Time of follow-upDoppler. LV end-diastolic and end-systolic volumes, as
well as ejection fraction, were measured by the biapical
Simpson disk method. Intraobserver and interobserver var-
iabilities, in our echocardiography laboratory, for exercise-
induced changes in LVEF using Simpson’s biplane
method were previously assessed and reported.9 The peak
E-wave and A-wave velocities of the mitral inﬂow were
measured using pulse-wave Doppler. Tissue Doppler im-
aging with pulse-wave Doppler at the level of septal and
lateral mitral annulus was used to measure e0. The average
of septal and lateral mitral annulus e0 peak velocity was usedto calculate the E/e0 ratio. AS severity was evaluated using
continuous-wave Doppler to measure the aortic trans-
valvular maximal velocities, and subsequent peak and mean
gradients were calculated using the simpliﬁed Bernoulli
equation. Aortic valve area was calculated using the conti-
nuity equation.10 Left atrial area was obtained by planimetry
of an end-systolic frame from the apical 4-chamber view.
All measures were indexed to body surface area.
A symptom-limited graded bicycle exercise test was per-
formed with an initial workload of 25W and an increase of
25W every 2 minutes in a semisupine position using a tilt
table. A 12-lead electrocardiography was monitored contin-
uously, and blood pressure was measured at rest and every
2 minutes during exercise. The test result was considered
abnormal if the patient presented one of the following criteria:
limiting dyspnea at low workload (i.e., during the 2 ﬁrst steps
of exercise), angina, syncope or near-syncope, increase in
blood pressure of <20 mm Hg, 2 mm ST-segment depres-
sion, or complex ventricular arrhythmias. By design, none of
the patients studied presented a positive stress test. At peak
exercise, the following echocardiographic parameters were
measured: AS severity (peak velocity, mean pressure, and
indexed valve area), LV systolic (indexed stoke volume and
ejection fraction) and diastolic function (E/e0 ratio)
parameters.
Venous blood samples for BNP level measurement were
drawn at rest before echocardiography. Chilled ethyl-
enediaminetetraacetic acidetreated tubes were centrifuged
immediately at 4,000 rpm (4C) for 15 minutes. Separated
plasma samples were processed by immunoﬂuorescence
assay (Biosite, Beckman Coulter, San Diego, California).
The inter- and intra-assay variations were 5% and 4%,
respectively. The assay detection limit was 1 pg/ml. BNP
changes were calculated as the difference between the last
BNP measurement obtained during the follow-up and the
baseline BNP measurement at inclusion:Annualized BNP changes were calculated as the BNP
changes divided by the time between baseline measurement
and last follow-up measurement:Patients were divided into 2 groups according to the
median of serial BNP changes (þ29 pg/ml). For continuous
variables, data are expressed as mean  SD, and group
comparisons were obtained with student t test. For cate-
gorical variables, data are summarized as percentages, and
group comparisons were obtained with chi-square test.
Normality distribution was tested with the Kolmogorov-
Smirnov test. Relation between serial BNP changes and
continuous parameters were analyzed with Spearman cor-
relation coefﬁcient. To identify independent predictors of
serial BNP changes, we used a multiple linear regression
Table 1
Demographic and clinical characteristics according to serial B-type natriuretic peptide changes
Variable Whole Cohort
(n [ 61)





Age (years) 70  13 68  12 71  13 0.364
Body surface area (m2) 1.8  0.2 1.8  0.2 1.9  0.2 0.483
Male gender 39 (64%) 21 (68%) 18 (60%) 0.529
Hypertension 34 (56%) 19 (61%) 15 (50%) 0.375
Diabetes mellitus 12 (20%) 6 (19%) 6 (20%) 0.949
Dyslipidemia 36 (59%) 16 (52%) 20 (67%) 0.232
Current smoker 18 (30%) 8 (26%) 10 (33%) 0.519
Coronary artery disease 14 (23%) 6 (19%) 8 (27%) 0.497
Atrial ﬁbrillation 6 (10%) 2 (6%) 4 (13%) 0.367
Chronic renal insufﬁciency 4 (7%) 2 (6%) 2 (7%) 0.973
BNP at baseline (pg/mL) 104  142 77  116 132  162 0.135
Heart rate (bpm) 71  11 71  10 70  12 0.545
Systolic blood pressure (mm Hg) 146  20 146  20 147  21 0.904
Diastolic blood pressure (mm Hg) 79  12 80  13 78  12 0.453
Exercise heart rate (bpm) 111  17 114  17 108  18 0.260
Exercise systolic blood pressure (mm Hg) 176  23 180  23 173  23 0.324
Exercise diastolic blood pressure (mm Hg) 87  16 88  15 85  18 0.562
Exercise capacity (Watts) 74  34 83  33 63  31 0.052
Figure 2. Mean BNP changes (A) and annualized BNP changes (B) according to BNP changes group (median). The open circles represent outliers and the
asterisk represent extreme outliers.
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analysis were automatically included in the multivariable
model. In addition, age, mean aortic pressure gradient, and
BNP at baseline were forced in the multivariable model
because of their well-established impact on the outcome. A
p value of <0.05 was considered statistically signiﬁcant.
Statistical analyses were performed using IBM SPSS
Statistics version 21 (IBM corp., Armonk).
Results
There were no signiﬁcant differences in demographic and
clinical characteristics and BNP level at baseline according to
serial BNP changes. A trend for a lower exercise capacity inthe high serial BNP changes group was observed (Table 1).
Mean BNP at baseline was 104  142 pg/ml (median 66,
range 5 to 700) and signiﬁcantly increased during the follow-
up (last measurement: mean ¼ 169 224 pg/ml, median 98,
range 8 to 1,380, p<0.001). Mean BNP change at follow-up
was þ65  130 pg/ml; median þ29, range 104 to þ675
(Figure 2, panel A). BNP level increased in 48 patients (79%),
multiplied by 2 in 16 (26%) and by 3 in 8 (13%) patients.
Duration of follow-up between the baseline and the last
measurement was 22  12.5 months (median 20, range 7 to
47). More than 1/2 of the patients (62%, n ¼ 38) had >3
measurements. Mean annualized BNP change wasþ44 84
pg/ml/year (median þ20, range: 128 to þ380; Figure 2,
panel B). At the last BNP measurement, 13 patients had
Table 2
Echocardiographic data according to serial B-type natriuretic peptide changes
Variable Whole Cohort
(n [ 61)







Peak aortic velocity (m/s) 3.7  0.7 3.7  0.6 3.8  0.7 0.469
Mean aortic pressure gradient (mm Hg) 37  14 35  13 39  16 0.319
Indexed valve area (cm2/m2) 0.53  0.13 0.55  0.11 0.51  0.15 0.193
LV geometry and function
Indexed mass (g/m2) 88  26 83  26 93  25 0.139
Indexed end-diastolic volume (mL/m2) 44  12 44  12 44  12 0.942
Indexed end-systolic volume (mL/m2) 14  6 14  6 14  5 0.744
Indexed stroke volume (mL/m2) 45  9 45  8 44  10 0.707
LV ejection fraction (%) 69  7 68  6 69  7 0.574
E/e0 ratio 11  4 9  3 12  5 0.022
Indexed left atrial area (cm2/m2) 9.6  2.4 9.2  2.2 10.1  2.6 0.167
Exercise parameters
AS severity
Peak aortic velocity (m/s) 4.2  0.8 4.1  0.8 4.3  0.8 0.424
Mean aortic pressure gradient (mm Hg) 48  20 47  19 49  23 0.703
Indexed valve area (cm2/m2) 0.57  0.13 0.58  0.11 0.55  0.14 0.572
LV geometry and function
Indexed stroke volume (mL/m2) 48  12 47  8 49  15 0.604
LV ejection fraction (%) 72  6 73  5 72  8 0.364
E/e0 ratio 12  4 11  3 13  5 0.068
Exercise-induced changes
Mean aortic pressure gradient (mm Hg) þ11  11 þ12  10 þ10  13 0.567
LV ejection fraction (%) þ4.0  4.3 þ5.2  4.5 þ2.5  3.7 0.026
LV ejection fraction by 4% 30 (49%) 20 (65%) 10 (33%) 0.047
E/e0 ratio þ1.2  2.7 þ1.2  2.6 þ1.1  3.0 0.877
AS ¼ aortic stenosis; LV ¼ left ventricular.
Figure 3. Relation between indexed left atrial area and (A) serial BNP changes and (B) annualized BNP changes.
444 The American Journal of Cardiology (www.ajconline.org)symptoms. A trend was observed for a greater increase in
annualized BNP in those patients (þ92  120 vs þ31  66
pg/ml/year, p ¼ 0.09).
By deﬁnition, all patients presented a moderate-to-severe
AS and a preserved LVEF. Patients with greater increasesin BNP during follow-up had higher E/e0 ratio at baseline.
There were no signiﬁcant differences inAS severity, left atrial
area, LVmass, and LV volumes and function between groups
(Table 2). Statistically signiﬁcant correlations were found
between BNP changes and indexed left atrial area (Figure 3,
Figure 4. Relation between E/e0 ratio at rest and (A) serial BNP changes and (B) annualized BNP changes.
Table 3
Correlation between serial B-type natriuretic peptide changes and
echocardiographic parameters
Variable r p-Value
BNP at baseline 0.24 0.066
Resting parameters
AS severity
Peak velocity 0.15 0.248
Mean pressure gradient 0.20 0.126
Indexed valve area 0.18 0.159
LV geometry and function
Indexed mass 0.25 0.067
Indexed end-diastolic volume 0.04 0.764
Indexed end-systolic volume 0.02 0.909
Indexed stroke volume 0.05 0.686
LV ejection fraction 0.10 0.490
E/e0 ratio 0.30 0.022
Indexed left atrial area 0.27 0.046
Exercise parameters
AS severity
Peak velocity 0.14 0.299
Mean pressure gradient 0.15 0.270
Indexed valve area 0.13 0.378
LV geometry and function
Indexed stroke volume 0.04 0.783
LV ejection fraction 0.01 0.957
E/e0 ratio 0.20 0.154
Exercise-induced changes
Mean aortic pressure gradient 0.03 0.840
LV ejection fraction 0.33 0.019
E/e0 ratio 0.05 0.974
AS ¼ aortic stenosis; LV ¼ left ventricular.
Valvular Heart Disease/Serial BNP Measurements in Aortic Stenosis 445panel A) and E/e0 ratio (Figure 4, panel A; Table 3). Similarly,
statistically signiﬁcant correlations were found between
annualized BNP changes and indexed left atrial area
(Figure 3, panel B) and E/e0 ratio (Figure 4, panel B).
Patients with greater increases in BNP during follow-up
had lower exercise-induced increases in LVEF. A trend infavor of higher exercise E/e0 ratio was also observed in these
patients. There were no signiﬁcant differences in exercise
AS severity parameters and exercise LVEF between groups
(Table 2). Statistically signiﬁcant correlation was found
between BNP changes and exercise-induced changes in
LVEF (Figure 5, panel A; Table 3). Similarly, annualized
BNP changes were correlated with exercise-induced
changes in LVEF (Figure 5, panel B). Patients with
exercise-induced increase in LVEF (4%) had signiﬁcant
lower BNP changes during follow-up (Figure 6).
After adjustment for age, mean aortic pressure gradient at
rest, and BNP level at baseline, multivariate analysis iden-
tiﬁed indexed left atrial area, E/e0 at rest, and exercise-
induced increase in ejection fraction as independent
determinants of serial BNP changes during follow-up
(Table 4). Moreover, after adjustment for age, E/e0 at rest,
and BNP level at baseline, indexed left atrial area (b ¼ 12.3
 4.1, p ¼ 0.004), mean aortic pressure at rest (b ¼ 2.0 
0.7, p ¼ 0.005), and exercise-induced increase in ejection
fraction (b ¼ 6.0  2.4, p ¼ 0.016) emerged as inde-
pendent determinants of annualized BNP changes.Discussion
The main ﬁndings of the present study show that, in
asymptomatic patients with preserved LVEF and moderate-
to-severe AS, (1) wide individual BNP variations can be
observed during regular monitoring; (2) increases in serial
BNP levels are related to the severity of diastolic burden
as evaluated by higher E/e0—an estimate of LV ﬁlling
pressure—and indexed left atrial area; and (3) limited con-
tractile reserve as manifested by lower exercise changes in
LVEF—latent LV systolic dysfunction—also signiﬁcantly
contributes to higher changes in BNP level during follow-up.
In AS, the single measurement of BNP level correlates
with valve area, diastolic function, functional status, and
symptomatic deterioration and may improve risk strat-
iﬁcation.11e13 Currently, little is known about serial changes
Figure 5. Relation between exercise-induced changes in LVEF and (A) serial BNP changes and (B) annualized BNP changes.
Figure 6. Mean BNP changes (A) and annualized BNP changes (B) according to exercise-induced changes in LVEF.
Table 4
Determinants of serial B-type natriuretic peptide changes: multiple linear
regressions
Variables Univariable Multivariable
p b SE p
Age 0.146 1.08 1.40 0.446
BNP at baseline 0.066 0.04 0.15 0.806
Mean aortic pressure gradient 0.126 1.94 1.18 0.107
Indexed left atrial area 0.046 20.1 6.8 0.005
Resting E/e0 ratio 0.022 10.0 4.2 0.020
Exercise changes in LV ejection fraction 0.019 8.5 4.1 0.044
LV ¼ left ventricular.
446 The American Journal of Cardiology (www.ajconline.org)in BNP levels in asymptomatic patients with AS and pre-
served LVEF. A small study including 29 asymptomatic
patients with moderate-to-severe AS demonstrated that the
average rate of increase in N-terminal fragment of pro-
hormone BNP in patients who developed symptoms washigher compared with those who remained asymptomatic
(þ26 vs þ7.2 pmol/L, p ¼ 0.014).14 Similarly, in a group of
43 initially asymptomatic patients, an increase in BNP was
noticed in 14 patients developing symptoms, whereas no
change was observed in those remaining stable.11 Unfortu-
nately, in both studies, cofactors associated with changes in
serial BNP levels were not assessed.
In our cohort of asymptomatic patients with AS and
preserved LVEF, we demonstrated for the ﬁrst time that
serial BNP changes during follow-up were associated with
subclinical LV dysfunction. Patients with higher BNP in-
creases were those with larger left atrial size and higher E/e0,
2 surrogate markers of LV diastolic burden, which has been
associated with a poor prognosis.12 Therefore, assessing the
changes in BNP levels may unmask a subgroup of asymp-
tomatic AS with a higher degree of LV diastolic dysfunc-
tion, which may precede symptom development.15
In addition, we showed that limited contractile reserve—
smaller exercise-induced increase in LVEF—was also an
independent predictor of BNP changes during follow-up. In
Valvular Heart Disease/Serial BNP Measurements in Aortic Stenosis 447AS, LVEF at rest, which often remains normal for long, may
underestimate the extent of intrinsic myocardial impair-
ment.16 Recently, it has been shown that limited contractile
reserve may identify a subset of patients who are at increased
risk of abnormal response to exercise and cardiovascular
events.17e19 The limited contractile reserve is thus intimately
related to latent myocardial dysfunction, which could be
easily detected by a signiﬁcant increase in serial BNP levels.
In a way, these data are similar to what has been observed in
patients with degenerative mitral regurgitation.20,21
The initial management of patients with AS is frequently
conservative because most of them are asymptomatic. How-
ever, additional tests to improve risk stratiﬁcation are required
as the individual outcomes are highly variable depending on
the degree of LV structural impairments, even with moderate
AS.4 BNP is the most commonly used biomarker in AS.
Although BNP carries reasonable prognostic information, it
lacks speciﬁcity when measured at a given time of the evo-
lution. Conversely, its regular monitoring can identify
patients with more advanced disease process who tend to
develop symptoms during follow-up.11,14 Indeed, a signiﬁ-
cant increase in BNP during follow-up identiﬁes patients with
latent LV systolic dysfunction and higher degree of LV dia-
stolic dysfunction. Monitoring changes in BNP level might
thus help to deﬁne the best timing of aortic valve replacement.
In practice, we suggest measuring BNP level at the initial
examination of AS and at regular intervals—every 6 to
12 months—during follow-up. An increase in serial BNP
level should lead to closer follow-up with a careful search for
unrevealed symptoms and repeat echocardiographic evalua-
tion. However, whether these serial BNP changes might be
used to predict the individual outcomes need to be addressed.
Some limitations need to be acknowledged. The duration
of follow-up and the interval between BNP measurements
were not standardized. We tried to counteract this limitation
using annualized BNP changes. Even if all patients were
followed up in our Heart Valve Clinic and received standard
clinical management, we cannot exclude that other factors,
such as medical therapy, changes in renal function, or stress
related to exercise testing, might have inﬂuenced the BNP
changes. Furthermore, because we used a tilt table to
perform exercise echocardiography, the continuous-wave
Doppler recordings were made almost only from the api-
cal position. This may have resulted in underestimation of
peak velocity in some patients.Acknowledgment: The authors thank M. Carmine
Celentano, R.N., for excellent technical assistance.Disclosures
Dr. Henri received grants from theMontreal Heart Institute
Foundation (Bourse du Bal du Cœur), the Department of
Medicine of the University of Montreal, and the Association
des Cardiologues du Québec, Montreal, Quebec, Canada. Dr.
Oury is a research associate at the F.R.S. - FNRS, Brussels,
Belgium. Pr. Lancellotti is supported by the Belgian National
Funds for Scientiﬁc Research (F.R.S.-FNRS T.0028.14),
Brussels, Belgium.1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang
OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P,
Vahanian A. A prospective survey of patients with valvular heart dis-
ease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur
Heart J 2003;24:1231e1243.
2. Carabello BA. Should severe aortic stenosis be operated on before
symptom onset? Aortic valve replacement should be operated on before
symptom onset. Circulation 2012;126:112e117.
3. Shah PK. Should severe aortic stenosis be operated on before symptom
onset? Severe aortic stenosis should not be operated on before symptom
onset. Circulation 2012;126:118e125.
4. Marechaux S, Hachicha Z, Bellouin A, Dumesnil JG, Meimoun P,
Pasquet A, Bergeron S, Arsenault M, Le Tourneau T, Ennezat PV,
Pibarot P. Usefulness of exercise-stress echocardiography for risk
stratiﬁcation of true asymptomatic patients with aortic valve stenosis.
Eur Heart J 2010;31:1390e1397.
5. Burgess MI, Jenkins C, Sharman JE, Marwick TH. Diastolic stress
echocardiography: hemodynamic validation and clinical signiﬁcance of
estimation of ventricular ﬁlling pressure with exercise. J Am Coll
Cardiol 2006;47:1891e1900.
6. Vahanian A, Alﬁeri O, Andreotti F, Antunes MJ, Baron-Esquivias G,
Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A,
Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler
G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO,
Windecker S, Zamorano JL, Zembala M. Guidelines on the manage-
ment of valvular heart disease (version 2012): Joint Task Force on the
Management of Valvular Heart Disease of the European Society of
Cardiology, European Association for Cardio-Thoracic Surgery. Eur
Heart J 2012;33:2451e2496.
7. Klaar U, Gabriel H, Bergler-Klein J, Pernicka E, Heger M,
Mascherbauer J, Rosenhek R, Binder T, Maurer G, Baumgartner H.
Prognostic value of serial B-type natriuretic peptide measurement in
asymptomatic organic mitral regurgitation. Eur J Heart Fail
2011;13:163e169.
8. Pizarro R, Bazzino OO, Oberti PF, Falconi ML, Arias AM, Krauss JG,
Cagide AM. Prospective validation of the prognostic usefulness of
B-type natriuretic peptide in asymptomatic patients with chronic severe
aortic regurgitation. J Am Coll Cardiol 2011;58:1705e1714.
9. Magne J, Mahjoub H, Dulgheru R, Pibarot P, Pierard LA, Lancellotti P.
Left ventricular contractile reserve in asymptomatic primary mitral
regurgitation. Eur Heart J 2013; Sep 7; Epub ahead of print.
10. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A,
Grifﬁn BP, Iung B, Otto CM, Pellikka PA, Quinones M. Echocardio-
graphic assessment of valve stenosis: EAE/ASE recommendations for
clinical practice. Eur J Echocardiogr 2009;10:1e25.
11. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel
H, Binder T, Pacher R, Maurer G, Baumgartner H. Natriuretic peptides
predict symptom-free survival and postoperative outcome in severe
aortic stenosis. Circulation 2004;109:2302e2308.
12. Lancellotti P, Moonen M, Magne J, O’Connor K, Cosyns B, Attena E,
Donal E, Pierard L. Prognostic effect of long-axis left ventricular
dysfunction and B-type natriuretic peptide levels in asymptomatic
aortic stenosis. Am J Cardiol 2010;105:383e388.
13. Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L,
Vanoverschelde JL, Carayon A, Gueret P. Predictors of outcome in
patients with severe aortic stenosis and normal left ventricular function:
role of B-type natriuretic peptide. Eur Heart J 2004;25:2048e2053.
14. Gerber IL, Legget ME, West TM, Richards AM, Stewart RA.
Usefulness of serial measurement of N-terminal pro-brain natriuretic
peptide plasma levels in asymptomatic patients with aortic stenosis
to predict symptomatic deterioration. Am J Cardiol 2005;95:
898e901.
15. Vanderheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K,
Van Schuerbeeck E, Bartunek J. Wall stress modulates brain natriuretic
peptide production in pressure overload cardiomyopathy. J Am Coll
Cardiol 2004;44:2349e2354.
16. Lancellotti P, Donal E, Magne J, Moonen M, O’Connor K, Daubert JC,
Pierard LA. Risk stratiﬁcation in asymptomatic moderate to severe
aortic stenosis: the importance of the valvular, arterial and ventricular
interplay. Heart 2010;96:1364e1371.
17. Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA.
Prognostic importance of quantitative exercise Doppler echocardiog-
raphy in asymptomatic valvular aortic stenosis. Circulation 2005;112:
I377eI382.
448 The American Journal of Cardiology (www.ajconline.org)18. Lancellotti P, Karsera D, Tumminello G, Lebois F, Pierard LA.
Determinants of an abnormal response to exercise in patients with
asymptomatic valvular aortic stenosis. Eur J Echocardiogr 2008;9:
338e343.
19. Van Pelt NC, Kerr AJ, Legget ME, Pasupati S, Whalley G, Wong S,
Zeng I, Stewart RA. Increased B-type natriuretic peptide is associated
with an abnormal blood pressure response to exercise in asymptomatic
aortic stenosis. Int J Cardiol 2008;127:313e320.20. Magne J, Mahjoub H, Pibarot P, Pirlet C, Pierard LA, Lancellotti P.
Prognostic importance of exercise brain natriuretic peptide in asymp-
tomatic degenerative mitral regurgitation. Eur J Heart Fail 2012;14:
1293e1302.
21. Magne J, Mahjoub H, Pierard LA, O’Connor K, Pirlet C, Pibarot P,
Lancellotti P. Prognostic importance of brain natriuretic peptide and
left ventricular longitudinal function in asymptomatic degenerative
mitral regurgitation. Heart 2012;98:584e591.
